Related Experiment Video
Updated: Mar 11, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt
1Department of Cardiothoracic Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China.
Abstract:
DDP (cisplatin) resistance in lung cancer has been widely reported. Baicalin is a flavone glycoside found in genus Scutellaria. However, the effects of baicalin on DDP resistance in lung cancer are unclear. The aim of present study was to investigate effects of combination of baicalin and DDP on proliferation and invasion of human lung cancer cells, and explore possible mechanisms. MTT assay was utilized to evaluate effects of baicalin and DDP on the proliferation of A549 and A549/DPP (DPP-resistant) human lung cancer cells. The probability sum method was used to determine effects of the drug combination. Transwell invasion assay was utilized to detect tumor cell invasion. The mRNA expression of MARK2 in A549 and A549/DPP cells was detected by qPCR. Protein expression of MARK2, p-Akt and Akt was detected by western blot analysis. Baicalin and DPP when used alone inhibited the proliferation of A549 and A549/DDP cells in a dose-dependent manner at 24 and 48 h. For A549 cells, baicalin (8 µg/ml) antagonized DDP (1, 2, 4 and 8 µg/ml) at 24 h. For A549/DDP cells, baicalin and DDP were additive when the concentration of DDP was 4 µg/ml at 24 h. Effects of baicalin and DDP on proliferation inhibition were additive and synergistic when concentrations of DDP were 8 and 4 µg/ml, respectively, at 48 h for both A549 and A549/DDP cells. When baicalin (8 µg/ml) and DDP (4 µg/ml) were combined, the inhibitory rate of tumor cell invasion increased markedly compared to DPP or baicalin alone groups in both A549 and A549/DDP cells. A549/DDP cells had significantly higher MARK2 mRNA levels and protein expression of MARK2 and p-Akt. Baicalin decreased MARK2 mRNA and protein expression of MARK2 and p-Akt in A549/DDP cells dose-dependently. In conclusion, baicalin and DDP were synergistic at inhibiting proliferation and invasion of human lung cancer cells at appropriate dosages and incubation time in the presence or absence of DDP resistance. The attenuation of DDP resistance was associated with downregulation of MARK2 and p-Akt.
Insights
Baicalin combined with cisplatin (DDP) shows synergistic effects in inhibiting lung cancer cell proliferation and invasion, even in DDP-resistant cells. This combination downregulates MARK2 and p-Akt, offering a potential strategy to overcome cisplatin resistance.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cisplatin (DDP) resistance is a significant challenge in lung cancer treatment.
- Baicalin, a flavone glycoside, has potential therapeutic properties, but its role in DDP resistance is not well understood.
- Investigating novel therapeutic strategies to overcome DDP resistance in lung cancer is crucial.
Purpose of the Study:
- To investigate the combined effects of baicalin and DDP on human lung cancer cell proliferation and invasion.
- To explore the underlying molecular mechanisms, focusing on MARK2 and Akt signaling pathways.
- To determine if baicalin can overcome DDP resistance in lung cancer.
Main Methods:
- Cell proliferation was assessed using MTT assays in A549 and DDP-resistant A549/DDP cells.
- Tumor cell invasion was evaluated using Transwell invasion assays.
- mRNA and protein expression levels of MARK2, p-Akt, and Akt were analyzed by qPCR and Western blot, respectively.
- The probability sum method was used to determine drug combination effects.
Main Results:
- Baicalin and DDP inhibited proliferation in a dose-dependent manner.
- The combination of baicalin and DDP demonstrated synergistic effects on inhibiting proliferation and invasion in both sensitive and resistant lung cancer cells at specific concentrations and incubation times.
- A549/DDP cells exhibited higher MARK2 and p-Akt expression; baicalin treatment dose-dependently decreased these markers.
Conclusions:
- Baicalin and DDP exhibit synergistic activity in inhibiting lung cancer cell proliferation and invasion, irrespective of DDP resistance.
- The observed chemosensitization is associated with the downregulation of MARK2 and phosphorylated Akt (p-Akt) signaling.
- This combination therapy holds promise for overcoming DDP resistance in lung cancer.
More Related Videos
Related Concept Videos
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

